The Supervisory Board of M1 Kliniken AG has appointed Katharina Zimmnau to the company's Executive Board, effective December 10, 2025. Zimmnau has served as Chief Financial Officer of M1 Kliniken AG since June 1, 2025. This appointment expands the leadership team of the European medical aesthetics provider during a period of significant international expansion. Attila Strauss, CEO of M1 Kliniken AG, expressed confidence in Zimmnau's capabilities, stating that her extensive experience in accounting, controlling, and process design will be instrumental in shaping the company's continued profitable growth trajectory.
The appointment comes as M1 Kliniken AG solidifies its position as the leading fully integrated provider of medical aesthetic services in Europe and Australia. The company's growth strategy has been systematic since late 2018, with international expansion forming the foundation for scalable future growth and further development of its global market position. M1 Kliniken AG currently operates 58 clinics across ten countries under the M1 Med Beauty brand, maintaining uniform high medical standards while offering treatments at market-leading prices. All procedures are performed exclusively by qualified physicians.
Beyond its network of aesthetic clinics, the Group operates the M1 Schlossklinik in Berlin, which represents one of Europe's largest and most modern facilities for plastic and aesthetic surgery. This clinic features four operating theaters and 35 beds, demonstrating the company's commitment to comprehensive medical infrastructure. The company maintains its corporate information at https://www.m1-kliniken.de.
The board expansion reflects the company's strategic focus on high standardization and consistent scalability as it continues to develop its international footprint. Zimmnau's financial expertise is expected to support the operational and strategic financial management required for sustained growth in the competitive medical aesthetics sector, where M1 Kliniken AG has established a significant presence through both clinical operations and surgical facilities. This leadership enhancement occurs as the company leverages its integrated model across clinical and surgical services to capture greater market share in the expanding global medical aesthetics industry.
